CACLP/SpaceGen will meet with you in Xiamen to jointly participate in the IVD spring event! ?? ??The 23rd China International Clinical Laboratory Equipment and Diagnostic Products Expo (CACLP) is scheduled to take place from March 21 to 23, 2026, in Xiamen, a scenic southern city in China, which serves as the location of SpaceGen's headquarters.?? As the host, SpaceGen extends a warm welcome to all participants. ??The CACLP assembles the world's leading experts, scholars, and industry elites in the in - vitro diagnostics (IVD) industry.?? It represents an outstanding platform for presenting state - of - the - art technologies, deliberating on industry trends, and exchanging business cooperation opportunities. We eagerly anticipate your presence and the opportunity to share our innovative solutions that are shaping the future of healthcare! ?? ?? March 21-23, 2026 ??Xiamen International Expo Center (No. 1, Yangfan Road, Fengxiang Street, Xiang'an District) #spacegen #CACLP #MedicalLaboratory #diagnostics #medlab #NGS #Oncology #innovation

The answer is false. Both men and women can get HPV. ??Most men have no symptoms after infection, but they can still pass the virus to their partners. HPV is the most common sexually transmitted infection in the world. Almost all cervical cancer cases are caused by persistent infection with high-risk HPV (hrHPV). ??HPV affects not only women’s health, but also public health worldwide. ??Early screening saves lives. Let’s work together for a cancer-free future.?? #SPACEGEN #HPV #InternationalHPVAwarenessDay #WomenHealth?

????We are proud to announce that Spacegen has been granted a U.S. patent for: ??"Library construction method for detecting endometrial cancer-related gene mutations based on high-throughput sequencing"(Patent No. : US 12,553,152 B2) ??This patent enables the detection of multiple gene mutations associated with endometrial cancer, including MSH2, PMS2, and MLH1 etc. , from a variety of sample types??. It allows for rapid library construction with a total turnaround time of 3 hours and only 30 minutes of manual operation, at a relatively low cost. It effectively addresses the current challenges in detecting whole-exome mutations of multiple genes in endometrial cancer using limited clinical samples.???? This milestone validates our innovation in precision oncology and women’s health????. It strengthens our global IP portfolio and supports more accurate, efficient molecular detection for endometrial cancer diagnosis and personalized treatment.???? Spacegen is committed to advancing precision diagnostics for better patient outcomes.?? #spacegen #Patent #EndometrialCancer #PrecisionMedicine #NGS #Biotechnology #WomenHealth #Innovation #HighThroughputSequencing #EarlyDetection #MolecularDiagnostics

Nipah virus infection is a zoonotic disease that can also spread among humans. The average incubation period of the Nipah virus is between 5 and 14 days. Symptoms, including high fever and headache, last for 3 to 14 days, followed by drowsiness, dizziness, and confusion. The virus can cause encephalitis and seizures. In severe cases, patients may fall into a coma within 24 to 48 hours. According to the World Health Organization, there are currently no approved vaccines or specific antiviral drugs for the Nipah virus. Treatment is limited to symptomatic relief using antiviral medications.

In the past 5 to 10 years, genomic technology has confirmed through mapping and comparing the genomic landscapes of the uterine and ovarian cancer foci in SEO - EC that the vast majority of SEO - EC is the result of endometrioid carcinoma originating in the uterine body metastasizing to the ovary. Molecular classification of endometrial cancer in ovarian and uterine double primary cancer has moved from research to clinical practice and has become a core tool for solving diagnostic dilemmas, optimizing treatment strategies, and accurately assessing prognosis. The "zero recurrence" feature of the POLEmut subtype supports a de - escalation treatment approach, the high invasiveness of the p53abn subtype requires intensified treatment, the MMRd subtype provides a target for immunotherapy, and the NSMP subtype requires further stratification in combination with more biomarkers - this "molecular - first" diagnosis and treatment model makes precision medicine for SEO - EC possible. In the future, with the standardization of detection techniques, the implementation of prospective investigations, and breakthroughs in targeted/immunotherapies, molecular classification is expected to further reshape the clinical management of SEO - EC, ultimately attaining the objectives of "personalized treatment" and "maximizing therapeutic efficacy while minimizing toxicity".

HER2 is an important driver gene of breast cancer and also an important target for targeted therapy. In the past, targeted therapy regimens against HER2 were mainly applied to patients with HER2 positivity. However, the most common form of breast cancer is in patients with HR-positive, HER2-negative subtypes. Although classified as HER2-negative, many of these patients actually exhibit some degree of HER2 expression (HER2 low expression or HER2 ultra-low expression). This means that a significant number of patient groups have long been in the dilemma of "having targets but no corresponding targeted drugs". The approval of new indications of T-DXd this time provides a clear and effective follow-up treatment plan for breast cancer patients after resistance to endocrine therapy. It not only opens up a new path of targeted therapy for traditional "HER2 negative" patients but also expands the beneficiary population of anti-HER2 therapy. #her2 #therapy #spacegen #gene #cancer #breastcancer